EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?

Clipper F. Young, Neeka Farnoudi, Jenny Chen, Jay H. Shubrook

Endocrines · 04.09.2023 · 4 (3) · 630-655

DOI: 10.3390/endocrines4030045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrines, online erschienen am 04.09.2023. Verfasst von Clipper F. Young und 3 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were once known as a class of glycemic-lowering agents to treat type 2 diabetes. As the evolving evidence from recent cardiorenal trials on these agents has shown—e.g., EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS Program, DAPA-CKD—disclosing their benefits beyond glycemic management, SGLT-2 inhibitors have stimulated a shift in the management of T2DM and its comorbidities, specifically preventing cardiovascular events in people with ASCVD, preventing heart failure hospitalizations, and delaying the progression of chronic kidney disease. As a result, their usage beyond glycemic management has been included in clinical practice guidelines. Although SGLT-2 inhibitors have shown promising results in cardiorenal outcomes, patients have not had equal access to these agents, at least in the United States, suggesting a systemic issue of health inequity. This review article explores the mechanisms by which cardiorenal benefits are offered, the results of the landmark clinical trials for these agents, and their place in therapy.

Zitieren

APA

Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023). Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?. Endocrines, 4(3), 630-655. https://doi.org/10.3390/endocrines4030045

Vancouver

Young CF, Farnoudi N, Chen J, Shubrook JH. Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?. Endocrines. 2023;4(3):630-655. doi:10.3390/endocrines4030045

BibTeX
@article{Young2023,
  author = {Young, Clipper F. and Farnoudi, Neeka and Chen, Jenny and Shubrook, Jay H.},
  title = {Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?},
  journal = {Endocrines},
  year = {2023},
  volume = {4},
  number = {3},
  pages = {630--655},
  doi = {10.3390/endocrines4030045}
}
Kostenlos starten →